KYNTRA BIO, INC.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
KYNB$3.90+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except per share amounts)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $50,482 | $81,553 |
| Short-term investments | — | 121,898 |
| Accounts receivable, net | 481 | 5,121 |
| Inventories | 3,155 | 17,173 |
| Prepaid expenses and other current assets | 31,542 | 40,038 |
| Current assets held for sale | 110,849 | 65,776 |
| Total current assets | 196,509 | 331,559 |
| Restricted time deposits | — | 1,658 |
| Property and equipment, net | — | 4,785 |
| Operating lease right-of-use assets | — | 64,939 |
| Other assets | 1,405 | 2,538 |
| Long-term assets held for sale | 16,611 | 18,050 |
| Total assets | $214,525 | $423,529 |
| Liabilities, redeemable non-controlling interests and deficit | ||
| Current liabilities: | ||
| Accounts payable | $5,064 | $15,778 |
| Accrued and other current liabilities | 62,035 | 132,987 |
| Deferred revenue | 27,290 | 12,740 |
| Operating lease liabilities, current | — | 12,647 |
| Current liabilities held for sale | 38,917 | 43,516 |
| Total current liabilities | 133,306 | 217,668 |
| Product development obligations | 17,012 | 17,763 |
| Deferred revenue, net of current | 114,708 | 157,555 |
| Operating lease liabilities, non-current | — | 65,033 |
| Senior secured term loan facilities, non-current | 73,092 | 71,934 |
| Liability related to sale of future revenues, non-current | 58,864 | 51,413 |
| Other long-term liabilities | 822 | 2,858 |
| Long-term liabilities held for sale | 356 | 1,504 |
| Total liabilities | 398,160 | 585,728 |
| Commitments and Contingencies (Note 12) | ||
| Redeemable non-controlling interests | 21,480 | 21,480 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2024 and 2023; 100,917 and 98,770 shares issued and outstanding at December 31, 2024 and 2023 | 1,009 | 988 |
| Additional paid-in capital | 1,668,620 | 1,643,641 |
| Accumulated other comprehensive loss | (5,732) | (6,875) |
| Accumulated deficit | (1,889,499) | (1,841,920) |
| Total stockholders’ deficit attributable to FibroGen | (225,602) | (204,166) |
| Nonredeemable non-controlling interests | 20,487 | 20,487 |
| Total deficit | (205,115) | (183,679) |
| Total liabilities, redeemable non-controlling interests and deficit | $214,525 | $423,529 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.